Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance StudyOriginal Research Published on 2023-05-042024-09-04 Journal: Advances in therapy [Category] 대상포진, [키워드] Mayo score Post-marketing surveillance ulcerative colitis vedolizumab α4β7 integrin [DOI] 10.1007/s12325-023-02500-6 PMC 바로가기 [Article Type] Original Research
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ studyOriginal Research Published on 2023-02-142024-09-04 Journal: Therapeutic Advances in Gastroenterology [Category] 대상포진, [키워드] anti-integrin agent Mayo score National Drug Program in Poland real-world prospective analysis response durability ulcerative colitis vedolizumab [DOI] 10.1177/17562848231151295 PMC 바로가기 [Article Type] Original Research